Who is sponsoring NCT03776266?

NCT03776266 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT03776266?

Interventions in NCT03776266: No intervention is required due to retrospective observational study.

What condition does NCT03776266 study?

NCT03776266 studies Erythrocyte Transfusion, Percutaneous Coronary Intervention, Revascularization.

Is NCT03776266 still recruiting?

NCT03776266 is currently completed. Last updated 28 March 2019.

Last reviewed 2019-03-28 · How we verify

NCT03776266: TFPCI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Long-term Clinical Outcomes and Patterns of Transfusion in PCI Patients: Retrospective Cohort Study

Completed Last updated 28 March 2019

What this trial tests

trial testing No intervention is required due to retrospective observational study in Erythrocyte Transfusion in 48,786 participants. Completed in 30 November 2018.

Timeline

5 October 2018

Primary endpoint
30 November 2018

30 November 2018

Quick facts

Lead sponsor	Samsung Medical Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	48,786
Start date	5 October 2018
Primary completion	30 November 2018
Estimated completion	30 November 2018
Sites	1 location across South Korea

Drugs / interventions tested

No intervention is required due to retrospective observational study

Conditions studied

Erythrocyte Transfusion — all drugs for Erythrocyte Transfusion →
Percutaneous Coronary Intervention — all drugs for Percutaneous Coronary Intervention →
Revascularization — all drugs for Revascularization →

Sponsor

Samsung Medical Center

Who can join

Eligibility, any sex, with Erythrocyte Transfusion or Percutaneous Coronary Intervention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A nationwide retrospective cohort study. To investigate the long-term patterns of transfusion and clinical outcomes of patients undergoing PCI.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Transfusion and clinical outcomes after percutaneous coronary intervention.
Choi J, Lee SH, Choi KH, Lee JM, et al · · 2024 · PMID 39122879 · DOI 10.1038/s41598-024-69385-5

Verify or expand the search:

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03776266 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 28 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03776266.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing